|
|
|
Celularity Founder, Chairman and CEO Dr. Robert Hariri delivers a formal corporate overview, followed by a Q & A session moderated by a Noble Capital Markets equity research representative. Return to the Investor Forum Event Page
Celularity is a clinical stage biotechnology company leading the next evolution in cellular medicine by developing off-the-shelf placenta-derived allogeneic cell therapies, including unmodified NK cells, genetically-modified NK cells, T cells engineered with a CAR (CAR T-cells), and mesenchymal-like adherent stromal cells (ASCs) targeting indications across cancer, infectious and degenerative diseases. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it will be able to develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies. |
Take it to the next level. It doesn’t cost a penny.
